TICKERNERD
Menu
FULCFULCHealthcare · Biotechnology

FULC Stock Forecast: Fulcrum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.74
+0.81% on the day

The 7 Wall Street analysts covering Fulcrum Therapeutics, Inc. hold a median 12-month price target of $3 — -19.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$285.4M
Ticker Nerd rank
33 / 100
Median analyst target
$3.00
Analysts covering
7
Total return, dividends reinvested
1W
−3.9%
1M
+4.2%
YTD
−66.9%
1Y
−43.3%
From 52W high
−74.4%
From 52W low
+19.1%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FULC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fulcrum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
65
Size
63
Growth
59
Accruals
59
Issuance
48
Revisions
48
Volatility
34
Momentum
13
Value
11

Quality (65): The business earns solid, repeatable profits on what it owns.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FULC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FULC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26FULCHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
0 Buy5 Hold2 Sell
Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits −19.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
3 June 2026JP MorganDowngradeUnderweight—
2 June 2026HC Wainwright & Co.DowngradeNeutral$25 → $3.00
2 June 2026Leerink PartnersDowngradeMarket Perform$24 → $4.00
2 June 2026Piper SandlerDowngradeUnderweight$23 → $3.00
2 June 2026StifelDowngradeHold$25 → $3.00
2 June 2026Truist SecuritiesDowngradeHold$17 → $4.00
12 Jan 2026JP MorganInitiatesOverweight—
11 Dec 2025Truist SecuritiesMaintainsBuy—
9 Dec 2025B of A SecuritiesMaintainsUnderperform—
8 Dec 2025Cantor FitzgeraldMaintainsOverweight—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Piper SandlerReiteratesOverweight—
8 Dec 2025RBC CapitalMaintainsSector Perform—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Nov 2025Truist SecuritiesInitiatesBuy—
30 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025RBC CapitalMaintainsSector Perform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
30 July 2025RBC CapitalMaintainsSector Perform—
29 July 2025HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FULC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FULC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Fulcrum Therapeutics, Inc. (FULC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.4%

Higher than 26% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FULC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FULCFulcrum Therapeutics, Inc.$285.4M
33
ELDNEledon Pharmaceuticals, Inc.$287.7M
32
SIONSionna Therapeutics, Inc.$288.3M
34
TTRXTurn Therapeutics, Inc.$281.8M
17
TRDAEntrada Therapeutics, Inc.$289.6M
51
NMRANeumora Therapeutics, Inc.$291.3M
36
IRDOpus Genetics, Inc.$293.8M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fulcrum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FULC news & analysis

Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

Newsfile Corp · 14 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced that it is investigating possible securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is inviting Fulcrum investors who have suffered losses, or individuals with information, to contact them.

Why it matters — The investigation signals potential legal and regulatory concerns regarding Fulcrum Therapeutics that FULC watchers would want to monitor.

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

Newsfile Corp · 7 Aug 2026negative

Kaplan Fox & Kilsheimer LLP has announced it is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is inviting investors who have suffered losses, or who have relevant information, to contact it regarding the investigation.

Why it matters — A securities investigation announced against Fulcrum Therapeutics could be significant for investors to watch as it relates to potential legal and regulatory scrutiny of the company.

Kaplan Fox Urges Fulcrum Therapeutics, Inc. (FULC) Investors to Contact the Firm About Possible Securities Law Violations

Newsfile Corp · 5 Aug 2026negative

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is urging Fulcrum investors who have suffered losses or who have information about the investigation to contact them.

Why it matters — A law firm investigation into possible securities violations could expose legal or compliance issues that may affect Fulcrum Therapeutics' financial standing and investor confidence.

Kaplan Fox & Kilsheimer LLP Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to an Investigation of Potential Securities Law Violations

Newsfile Corp · 3 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is inviting affected investors who have suffered losses, or those with relevant information, to contact it.

Why it matters — A securities-law investigation introduces potential legal risk for Fulcrum Therapeutics that FULC watchers would want to track.

FAQ

Frequently asked questions about FULC stock

What is the FULC stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Fulcrum Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FULC stock a buy right now?

Of the 7 analysts covering Fulcrum Therapeutics, Inc., 0 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Fulcrum Therapeutics, Inc. 33 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FULC?

As at 15 Aug 2026, Fulcrum Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (65 of 100).

Will FULC stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -19.8% from the last close, and Ticker Nerd's factor model ranks Fulcrum Therapeutics, Inc. 33 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FULC stock forecast for 2030?

No analyst covering Fulcrum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FULC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has FULC stock performed over the past year?

Fulcrum Therapeutics, Inc. returned -43.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fulcrum Therapeutics, Inc. do?

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to treat genetically defined rare diseases in areas of high unmet medical need.

What is the latest news on FULC?

The most recent item we track (Newsfile Corp, 14 Aug 2026): "Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations". Kaplan Fox & Kilsheimer LLP announced that it is investigating possible securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is inviting Fulcrum investors who have suffered losses, or individuals with information, to contact them.

Company

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to treat genetically defined rare diseases in areas of high unmet medical need. The company employs proprietary technology to identify drug targets that modulate gene expression, addressing the root causes of gene mis-expression. Its lead product candidate, losmapimod, targets facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating muscle disorder. Additional programs include FTX-6058 and pociredir, small molecules designed to increase fetal hemoglobin expression for sickle cell disease, beta-thalassemia, and other hemoglobinopathies, as well as efforts in diamond-blackfan anemia, bone marrow failure syndromes, and fibrotic disorders. Fulcrum Therapeutics Inc. emphasizes a patient-centered approach, aiming to transform the lives of patients and caregivers through innovative gene control mechanisms. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company plays a key role in advancing treatments for underserved rare disease populations.

CEO Mr. Alexander C. Sapir · 9 employees · United States · https://www.fulcrumtx.com